PTCT:NASDAQ
PTC Therapeutics, Inc.
$59.67
arrow_downward
-0.42%(-0.25) 1D
$59.67
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 14, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$59.30
High
$60.69
Low
$58.80
Mkt. cap
4.98B
Avg. vol.
1.18M
Volume
0.00
52-wk high
$90.87
52-wk low
$58.80
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
Open
$59.30
High
$60.69
Low
$58.80
Mkt. cap
4.98B
Avg. vol.
1.18M
Volume
0.00
52-wk high
$90.87
52-wk low
$58.80
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
News stories
From web sources and news partners
MarketBeat
·
1 day ago
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock
Stock Titan
·
1 day ago
After exercising options at $39.42, PTC Therapeutics (PTCT) CLO Boulding sells 192 shares.
Investing.com
·
2 days ago
PTC Therapeutics director Glenn Steele sells $781,920 in shares
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com